v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 4,129 $ 6,276 $ 12,571 $ 13,844
General and administrative 5,012 13,823 21,876 28,382
Settlement expense       21,366
Reimbursement of expenses from Relief Therapeutics       (771)
Total operating expenses 9,141 20,099 34,447 62,821
Loss from operations (9,141) (20,099) (34,447) (62,821)
Other (income) expenses:        
Gain on extinguishment of debt       (121)
Interest income (95)   (119)  
Interest expense   5 3 16
Change in fair value of warrant liability 37 16,537 (236) (823)
Change in fair value of Earnout Cash liability   408 (4,582) 763
Total other (income) expenses (58) 16,950 (4,934) (165)
Net loss (9,083) (37,049) (29,513) (62,656)
Deemed dividend       (255,822)
Net loss attributable to common stockholders $ (9,083) $ (37,049) $ (29,513) $ (318,478)
Net loss per share:        
Basic $ (0.14) $ (0.72) $ (0.45) $ (1.45)
Diluted (0.14) (0.72) (0.45) (1.45)
Net loss per share attributable to common stockholders:        
Basic (0.14) (0.72) (0.45) (7.36)
Diluted $ (0.14) $ (0.72) $ (0.45) $ (7.36)
Weighted average common shares outstanding:        
Basic 66,449,593 51,739,452 65,532,409 43,290,675
Diluted 66,449,593 51,739,452 65,532,409 43,290,675

Source